CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Farmaexplorer.it
Cardiobase

Rivaroxaban has shown non-inferiority compared to Enoxaparin in patients with acute symptomatic deep vein thrombosis


The Phase III EINSTEIN-DVT clinical trial of the oral anticoagulant Rivaroxaban ( Xarelto ) demonstrated non-inferiority compared to the standard of care for the prevention of recurrent venous thromboembolism ( VTE ) in patients with acute symptomatic deep vein thrombosis ( DVT ), with a comparable safety profile.

In the study, oral Rivaroxaban demonstrated non-inferiority for the primary efficacy outcome, defined as the cumulative incidence of symptomatic recurrent deep vein thrombosis and non-fatal or fatal pulmonary embolism, in patients with acute symptomatic deep vein thrombosis compared with the current standard of care of Enoxaparin ( Lovenox ) followed by a vitamin K antagonist ( VKA ) ( 2.1% vs 3%, respectively; p


Indietro